Tradeline, Inc. filters and categorizes new-construction and industry news from regional and professional journals across the country. Here you will find new projects, products, and regulatory updates.
Industry News
Ryvu Therapeutics Completes R&D Center for Innovative Drugs
Ryvu Therapeutics completed construction in June of 2020 on the R&D Center for Innovative Drugs in Krakow, Poland. Accommodating approximately 300 employees, the $20 million headquarters and research facility will enable the clinical-stage biopharmaceutical company to accelerate the development of novel small molecule therapies that address emerging targets in oncology.
Husson University Breaks Ground on Center for Business
Husson University broke ground in June of 2020 on the $17.2 million Center for Business in Bangor, Maine. Offering technology-rich classrooms for experiential learning, the 42,500-sf structure will feature the IEX Center, a unique facility that will leverage virtual and augmented reality modalities to deliver immersive experiences related to courses at Husson.
University of Mount Union to Implement Social Distancing Learning Model
The University of Mount Union has created an innovative plan to safely resume instructional and residential operations in fall of 2020 in Alliance, Ohio. As well as making modifications to all areas of campus including classrooms, housing, dining areas, and group meeting spaces, the university will implement the Social Distancing Learning Model which includes both face-to-face and remote instruction.
Genomic Partnership Wales Designs Research Facility
Genomic Partnership Wales is planning to construct a research facility in Cardiff in the United Kingdom to accelerate the development of pharmaceutical therapies. Created by a consortium of government, academic, and medical partners, the project involves the redevelopment of an existing two-story building to provide leading-edge genetics labs, seminar rooms, treatment suites, offices, freezer rooms, and support. The facility will include CL2 biocontainment research suites to ensure compliance with the UK's HBN 15 regulations for pathology services.
Catalent Increases Bloomington Manufacturing Capacity for SARS-CoV-2 Vaccine Candidate
Catalent is rapidly scaling up its manufacturing capacity in Bloomington to enable production of a SARS-CoV-2 vaccine candidate that is currently being by developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The collaboration involves joint investment from Catalent and Janssen to enable large-scale commercial manufacturing by January of 2021, with segregated cGMP production lines operating 24/7 to create approximately a billion doses.